Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA | Zendy

Darren K. McGuire | Zendy; John H. Alexander | Zendy; Odd Erik Johansen | Zendy; Vlado Perkovic | Zendy; Julio Rosenstock | Zendy; Mark E. Cooper | Zendy; Christoph Wanner | Zendy; Steven E. Kahn | Zendy; Robert D. Toto | Zendy; Bernard Zinman | Zendy; David Baanstra | Zendy; Egon Pfarr | Zendy; Sven Schnaidt | Zendy; Thomas Meinicke | Zendy; Jyothis T. George | Zendy; Maximilian von Eynatten | Zendy; Nikolaus Marx | Zendy

Open Access

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Author(s) -

Darren K. McGuire,

John H. Alexander,

Odd Erik Johansen,

Vlado Perkovic,

Julio Rosenstock,

Mark E. Cooper,

Christoph Wanner,

Steven E. Kahn,

Robert D. Toto,

Bernard Zinman,

David Baanstra,

Egon Pfarr,

Sven Schnaidt,

Thomas Meinicke,

Jyothis T. George,

Maximilian von Eynatten,

Nikolaus Marx

Publication year - 2019

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.038352

Subject(s) - medicine , linagliptin , diabetes mellitus , ejection fraction , heart failure , dipeptidyl peptidase 4 inhibitor , type 2 diabetes mellitus , type 2 diabetes , kidney disease , cardiology , placebo , endocrinology , pathology , alternative medicine

Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin), a cardiovascular outcomes trial that enrolled participants with type 2 diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research